Screener
AbCellera Biologics Inc. ABCL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|
| Net cash used in investing activities | (23,876) | (13,740) |
| Cash flows from financing activities: | ||
| Proceeds from deferred government contributions and other | 2,595 | 13,585 |
| Net cash provided by financing activities | 2,595 | 13,585 |
| Effect of exchange rate changes on cash and cash equivalents | 1,351 | (468) |
| Decrease in cash and cash equivalents | (63,888) | (8,223) |
| Cash and cash equivalents and restricted cash, beginning of period | 183,615 | 155,249 |
| Cash and cash equivalents and restricted cash, end of period | $119,727 | $147,026 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s financing cash flow?
- AbCellera Biologics Inc. (ABCL) reported financing cash flow of $6.39M in Q2 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about AbCellera Biologics Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude